Please login to the form below

Not currently logged in
Email:
Password:

GSK/Neurocrine depression drug fails

A potential therapy for depression developed by GlaxoSmithKline and Neurocrine Biosciences failed to meet its goal in a mid-stage clinical trial

A potential new therapy for major depression that is being developed through a partnership between GlaxoSmithKline (GSK) and Neurocrine Biosciences failed to meet its goal in a mid-stage clinical trial.

Top-line efficacy and safety results from a phase II trial of Corticotropin Releasing Factor (CRF1) receptor antagonist GSK561679 found that the drug was no more effective than placebo in patients experiencing a major depressive episode.

The study, which was conducted by GSK, enrolled 150 patients who were randomised to receive either 350mg of GSK561679 daily or placebo. The primary endpoint was change from baseline in the Bech Melancholia scale at week six. The Bech Melancholia scale is designed to measure the severity of depressive symptoms in patients with depressive illness.

Neurocrine said it will meet with GSK once the full clinical data set is complete, which is targeted for within the next few months, to decide on the next steps for the development programme. Meanwhile, clinical trials are ongoing to test the drug as a treatment for post traumatic stress disorder, anxiety and alcoholism.

Neurocrine and GSK signed a worldwide research, development and commercialisation agreement for Corticotropin Releasing Factor Receptor Antagonists for psychiatric, neurological and gastrointestinal diseases in 2001.

15th September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics